Abstract
influenced both the rate and mechanism of resistance evolution. Specifically, we found that 23 the current clinical practice of high amoxicillin to clavulanate ratios resulted in the most rapid 24 failure due to the evolution of gene dosing responses. Increased plasmid copy number 25 allowed E. coli to increase β-lactamase dosing and effectively titrate out the low quantities of 26 clavulanate, restoring amoxicillin resistance. In contrast, we found high clavulanate ratios 27 were more robust -plasmid copy number did not increase, although porin or efflux resistance 28 mechanisms were found, as in all drug ratios. Our results indicate that by changing the ratio 29 of adjuvant to antibiotic we can slow and steer the path of resistance evolution. We therefore 30
Introduction

34
The current crisis of antibiotic resistance is grounded in the ability of bacterial pathogens to 35 rapidly evolve and adapt to novel stressors like antibiotics (1) . Even for the same drug many 36 different mechanisms confer resistance, often with varying transmissibility, costs and cross 37 resistances (2-5). Examples of resistance have been found for all currently used antibiotics 38 and recently clinicians have begun to face pathogens that are resistant to all available 39 antibiotics (4, 6-8). 40
In addition to the ongoing search for new drugs (9) , an important direction in combating 41 resistance is the restoration of antibiotic sensitivity to existing drugs via the use of anti-42 resistance compounds or adjuvants (10-12). Antibiotic adjuvants are compounds that do not 43 affect the growth of bacteria on their own but instead enhance the activity of antibiotics, by 44 inhibiting mechanisms of resistance (13, 14) . For example β-lactamase inhibitors prevent β-45 lactamase enzymes from degrading β-lactam antibiotics (15). β-lactamse mediated resistance 46 is especially problematic for gram negative pathogens where these enzymes are common and 47 disseminated on plasmids (10, 16, 17). Therefore β-lactamase β-lactamase inhibitor (BLBLI) 48 combinations will restore β-lactam sensitivity of β-lactamse carrying strains without using 49 novel antibiotics or antibiotics of last resort like carbapenems (16) . 50
In this study we use co-amoxiclav (brand name Augmentin), a BLBLI combination of 51 amoxicillin and clavulanate (clavulanic acid) that has been widely used globally since 1981 52 (18), and is on the WHO list of essential medicines (19). Amoxicillin is a bacteriocidal β-53 lactam antibiotic that inhibits synthesis of the bacterial cell wall (17). The adjuvant 54 clavulanate has a similar structure to β-lactam antibiotics and thus acts as a competitive 55 inhibitor of many β-lactamase enzymes (15). By preventing amoxicillin cleavage, clavulanate 56 suppresses the resistance phenotype making amoxicillin effective again. 57
Despite the efficacy of BLBLI combinations like co-amoxiclav resistance is still possible, 58 either by altering the effect of amoxicillin or the effect of clavulanate. Clavulanate is 59 ineffective against resistance mechanisms that don't involve β-lactamase expression. Thus 60 direct resistance to amoxicillin, via altered penicillin binding protein structure, reduced porin 61 expression or increased efflux pump expression can lead to resistance to co-amoxiclav (15). 62
On the other hand increased production of lactamase enzymes overwhelm the clavulanate 63 (20) and inhibitor resistant β-lactamase enzymes reduce (or abolish) the effect of clavulanate 64
Despite the recent interest in adjuvants, the relative doses of the components in adjuvant 66 therapies have received little attention, with clinical amoxicillin : clavulanate ratios varying 67 from 2:1 to 16:1 (22), with an increase in amoxicillin more recently to combat resistance 68 (18). Here we mathematically model and empirically map the synergy between amoxicillin 69 and clavulanate in controlling a population of β-lactamase expressing E. coli. We then go on 70 to demonstrate that drug ratios that are equally effective in their initial levels of control can 71 produce distinct evolutionary responses. Specifically, we find that current high amoxicillin 72 ratios lead to the rapid evolution of resistance via increased β-lactamase expression, while 73 low amoxicillin ratios with equal initial efficacy are more robust, and maintain the efficacy of 74 our meagre pool of β-lactamase inhibitors. We therefore suggest the use of increased 75 clavulanate dosing regimens to slow the rate of resistance evolution. 76
Results
78
Theoretical model
79
We begin by developing a simple qualitative model for bacterial population dynamics under 80 the control of co-amoxiclav as examples of β-lactam antibiotics and a β-lactamase inhibiting 81 adjuvants ( Figure S3 , Text S1). The model predicts that the two compounds will show strong 82 synergy when controlling a pathogen with an existing β-lactamase resistance gene (Figure  83 1a), as is seen in our experimental results (Figure 1b) . We next introduce two resistance 84 mechanisms to the model, direct (non-β-lactamase) mediated resistance via 85 target/permeability mutations (fig 2a) , or β-lactamase over-production (fig 2b) and ask how 86 co-amoxiclav component dosing regimens impact selection for each mechanism. 87 
). Carrying capacity of the system is normalised to one, so equilibrium density will be one in the absence of drugs and costly resistance. Parameters capture resistance to amoxicillin via β- The growth benefit
of increased β-lactamase production (z) can be greatly reduced without affecting equilibrium density or benefit of direct resistance by reducing the proportion of amoxicillin. Parameter values are the same as in Figure 1a . See Text S1 for derivation of equations. c) We chose 5 drug ratios (different coloured lines from the origin) which according to our model and data ( Figure 1 ) should impose similar inhibition (at 3 different strengths of inhibition) but select for different resistance mechanisms.
The model predicts that non-β-lactamase resistance mutations will be selected in proportion 89 to the efficacy of the combination treatment (Figure 2a) . In contrast, β-lactamase over-90 production mutants show a more interesting pattern with maximal selection biased towards 91 all sequenced populations is shown on the left. Red indicates that a mutation is at high frequency and blue indicates that the mutation is at low frequency or absent. The white box indicates that the mutation is present in the population but a frequency is unable to be assigned to it. Mutations are identified by their position and prefixed by P or C for plasmid or chromosome respectively. Only polymorphic mutations that were found at a frequency equal to or greater than 20% in one or more lines are shown. All mutations are listed in the Data S1. 
Discussion
137
In this study we have demonstrated that the synergistic interaction between a β-lactam 138 antibiotic and a β-lactamase inhibitor (adjuvant) can lead to distinct phenotypic and genomic 139 paths to resistance evolution in a ratio-dependent manner, with potential consequences for the 140 sustainable management of adjuvant therapies. Recent work has suggested that the ratio of 141 drugs used in combination therapies may affect selection for resistance (25-27). However 142 drug interactions make it difficult to separate the effect of drug ratio from the inhibitory 143 strength of the treatment, which has a well-established effect on the evolution of drug 144 resistance (3). We find that low amoxicillin treatments confer weaker selection for resistance 145 (Figure 3) , even when the inhibitory effect of the drug combination on the ancestor is similar. 146
As expected (3), resistance generally evolves faster when the inhibitory effect is greater( figure 3 and 4) , however, all lines selected in high clavulanate environments had least 148 resistance, regardless of inhibitory effect (Figure 3a) . 149
Our mathematical model (Figure 2b and S3) suggests that increased β-lactamase expression 150 is more strongly selected with high proportions of amoxicillin, because when clavulanate is 151 not in excess its effect can be titrated out by increasing lactamase expression. On the other 152 hand selection for direct resistance only depends on the inhibitory strength of the drug 153 combination, because this is equivalent to the amoxicillin concentration experienced by the 154 bacterium after some proportion has been broken down by lactamase. Consistent with our 155 model, we found that lines selected at high amoxicillin proportions grew well in high 156 amoxicillin environments but poorly in low amoxicillin environments (Figures 3d-f ). These 157 lines had increased plasmid copy number (and thus β-lactamase expression) through parallel 158 mutations in repY (Figure 5 ), which protects against amoxicillin but not in the presence of 159 high levels of clavulanate. On the other hand, lines selected in high clavulanate environments 160 grew poorly, but consistently across all amoxicillin proportions. These lines only acquired 161 direct resistance to amoxicillin through parallel mutations affecting porins and efflux pumps, 162 a resistance mechanism seen across all amoxicillin proportions. This resistance mechanism 163 provides a benefit independent of amoxicillin proportion, as it only depends on amount of 164 non-cleaved amoxicillin. In addition to multiple different mutations in genes with similar 165 functions we find some identical mutations in different lines indicating that specific 166 mutations may be adaptive as is likely the case for repY mutations. Mock passaged blank 167 wells showed no evidence of cross contamination. Sequencing of a control evolved line 168 indicated that it was also polymorphic at chromosome position 4,294,083 suggesting this 169 polymorphism was present in the ancestral population or is an artefact of our sequence 170
analysis. 171
Although the shape of drug interactions have recently been shown to evolve in bacteria (27), 172 to our knowledge this is the first time that this has been reported for antibiotic adjuvant 173 combinations, or that these changes have been linked to the mechanisms of drug action. Our 174 results suggest that dosing regimens with higher amounts of clavulanate will more effectively 175 slow the evolution of resistance by rendering some resistance types ineffective; specifically 176 beta-lactamase dose-response mutations will be less able to titrate out the effect of larger 177 amounts of beta-lactamase inhibitor. Since its introduction the dosage of amoxicillin in co-178 amoxiclav tablets has increased from 250mg to 875mg, to combat amoxicillin resistance, 179 however the dosage of clavulanate has remained the same at 125mg. There are many other 180 considerations when designing dosing regimens including pharmacokinetics/ 181 pharmacodynamics and toxicity (although amoxicillin and clavulanate are well tolerated, (28, 182 29)), but the potential for resistance is increasingly important. Increased β-lactamase 183 expression is a common resistance mechanism, particularly when plasmid borne (20) . 184 Therefore, we suggest that the amount of clavulanate could be increased to reduce selection 185 for increased lactamase expression without affecting the fitness of other resistance 186 mechanisms. This would have the added benefit of reducing selection for plasmid based 187 resistance, which is both easily mobilised and can increase evolvability (20). 188
As our supply of antibiotics becomes limited there has been greater interest in extending the 189 lifetime of antibiotics through combination with adjuvants, and β-lactams are no exception 190 (9). As antibiotics have been developed for longer than adjuvants we have many β-lactam 191 antibiotics which could be more effective if combined with an adjuvant but relatively few β-192 lactamase inhibitors to combine them with (15). Therefore, it has been argued that adjuvants 193 should be conserved over antibiotics (13), with the antibiotic component of a combination 194 being replaced when resistance renders it ineffective through direct resistance mechanisms. 195
Our results with co-amoxiclav suggest that using β-lactamase inhibitors at high 196 concentrations would do exactly this by steering resistance away from β-lactamase over-197 expression and towards direct mechanisms of resistance -at which point the β-lactam 198 component could in principle be replaced. In practice, the potential enrichment of broad-199 specificity resistance mechanisms will limit the set of replacement options. In general we 200 argue that our ability to manage infections on both the patient and public health scales will 201 require greater investment into the evolutionary consequences of existing and potential 202 treatment regimens. 203
Methods
204
Strains and media
205
Escherichia coli strain MG1655 containing a naturally occurring pCT plasmid (30) and 206 defective for horizontal transfer due to a mutation in the trbA gene (31) was used as the 207 ancestor of all selection lines and is henceforth referred to as the ancestor. The strain was 208 produced in the lab of Dr Ben Raymond (31) and kindly provided. The pCT plasmid is a 209 large naturally occurring plasmid containing the CTX-M-14 extended spectrum β-lactamase. 210
The pCT plasmid is stable, however prior to incubation for experimental evolution and 211 growth dynamics assays the ancestor was grown in the presence of 100µg/ml ampicillin to 212 maintain the pCT plasmid. For phenotyping of experimentally evolved strains pre-culture 213 was without antibiotics to reduce any non-genetic effects of exposure to antibiotic treatment. 214
Experimental evolution was conducted in a defined minimal medium with the following 215 recipe. M9 medium base (containing 6.78 mg/ml Na 2 HPO 4 , 3 mg/ml KH 2 PO 4 , 0.5 mg/ml 216 NaCl and 1 mg/ml NH 4 Cl) supplemented with 1mM MgSO4, 0.1mM CaCl2, 0.4% (v/v) 217 glycerol, 0.02% casamino acids, 0.5µg/ml thiamine and Hutners trace elements (32) at 1X 218 concentration. Initial checkerboard assays were conducted in Luria Bertani (LB) broth. 219
Clavulanate (in the form of potassium clavulanate, Fluca analytical) and amoxicillin (LKT 220 laboratories) were supplied in powdered forms, stored at 4 o C and used to make stocks in 221 deionised water. These stocks were stored at 4 o C according to manufacturer's instructions, 222 liquid stocks were not kept for longer than 14 days to minimise degradation of the 223
compounds. 224
To test antibiotic sensitivity of the ancestral strain the ancestor was grown for 22 hours in LB 225 broth in the presence of increasing clavulanate and amoxicillin, at all possible combinations 226 of the two drug concentrations (checkerboard assay, Figures 1b and S1 ). From these 5 227 different ratios of amoxicillin and clavulanate, as well as associated iso-inhibitory doses were 228 identified for each ratio. These were tested in minimal medium to confirm that growth was 229 not significantly affected by drug ratio, but was affected by the strength of the drug dose 230 (figure S2). The chosen concentrations and relationships between them are shown in Figure  231 2c. 232
Experimental evolution
233
To test its ability to adapt to different drug doses, E coli was selected against varying drug 234 regimens defined by the relative proportion of amoxicillin (p Selection, p s ) and dose strength 235 (V s ), as in figure 2c. A mid exponential culture the ancestor was washed and diluted in 236 minimal medium. This was aliquotted into 48 wells in the centre of a 96 well plate, which 237 were then made up to a final volume of 200µl by adding reconstituted clavulanate and 238 amoxicillin, starting densities were OD = 0.01. Experimental evolution lines were set up 239 corresponding to 5 drug ratios at 3 different strengths, plus one line which was not exposed to 240 drugs, each replicated 3 times (48 independent lines), plus 3 replicate sterile wells with no 241 drugs (which were still passaged). Plates were incubated statically at 37 o C for 22 hours for 242 each passage. After each growth cycle wells were mixed using a pipette to re-suspend any 243 clumps of bacteria. The optical density of the wells was then measured and used to transfercells to a fresh microwell plate so that each line started at an OD (600nm) of 0.01. were for each plate were corrected using the growth of controls (in the absence of drugs). p S 268 is undefined for the control lines (selected without drugs) so these were tested against every 269 different drug environment. 270
Statistics
271
All statistics were performed in R (33). Full models were produced using relevant main 272 effects and interactions (statistical tables in supplementary information). Fixed effects models 273 were fitted using the glm function with a Gaussian error distribution and identity link 274 function. For data sets where multiple measures were taken from each strain, a mixed effects 275 model was used to take into account the effect of strain as a random effect, this was fittedusing the lme function in the nlme package (34). As there were many explanatory variables 277 for this data, 2 models are fitted to 2 subsets of the data. One data set includes all data where 278 strains are tested for resistance to the same dose strength they are selected against (at varying 279 drug ratios). This will investigate whether resistance evolved to one drug ratio confers 280 resistance to other drug ratios. The other set includes all data where strains are tested for 281 resistance to the same ratio they were selected against (at different dose strengths). This 282 model investigates whether resistance selected at one dose strength confers resistance to 283 others. Both these data sets include the 45 data points (one per evolved line) where both ratio 284 and strength of assay are the same as those for selection (i.e the selection conditions for that 285 line). 286
The maximal model was reduced to a minimal model in a stepwise manner. At each step of 287 model reduction all terms that were not currently included in an interaction were tested for 288 significance as grounds for including them in a model. Terms were dropped if the result of an 289 F test (for fixed effects models) or likelihood ratio test (for mixed effects models) comparison 290 of models with and without the term of interest was not significant at α=0.05 (i.e. accepting 291 the null hypothesis of no significant effect of the term). At each step only one term could be 292 dropped so where several effects were non-significant the new model with the lowest AiC 293 (Akaike information criterion) was chosen as the best model reduction at that step. When no 294 terms (not included in higher order interactions) could be dropped without a significant effect 295 this was considered the minimal model. Statistical support for all terms in the minimal 296 models was assessed as above but through comparison of the minimal model and the minimal 297 model with the term dropped. Full statistical results are reported in statistical tables in the 298 supplementary information. 299
Sequencing and Bioinformatics
300
To test whether different drug ratios select for different resistance mutations we sequenced 301 evolved populations selected against the highest dose strengths after 6 passages of 302 experimental evolution. The ancestral strain and one of the 3 populations evolved in the 303 absence of drugs was also sequenced. Library preparation and paired end MiSeq sequencing 304 was performed by Edinburgh genomics. Obtained sequences were aligned to both the 305 MG1655 reference (35) and the pCT plasmid reference (30) and polymorphisms identified 306 using breseq in polymorphism mode using default parameters (36). 307
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